Yuspian Nur, Muhammad Ihda Hl Zein, Irkham Irkham, Shabarni Gaffar, Toto Subroto, Yeni Wahyuni Hartati
{"title":"Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection.","authors":"Yuspian Nur, Muhammad Ihda Hl Zein, Irkham Irkham, Shabarni Gaffar, Toto Subroto, Yeni Wahyuni Hartati","doi":"10.5599/admet.2404","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Chronic myeloid leukaemia (CML) is one of the most lethal types of leukaemia and can rapidly progress if not treated properly. Therefore, having an effective diagnostic strategy is crucial. Various methods are available for diagnosis, including electrochemical biosensors with aptamer bioreceptors.</p><p><strong>Experimental approach: </strong>In this study, we immobilized the KK1D04 aptamer on a screen-printed carbon electrode (SPCE) supported by CeO<sub>2</sub> nanoparticles (CeO<sub>2</sub>NPs) to detect K562 cells, a type of CML cell line. Several parameters were optimized to enhance the aptasensor response using the Box-Behnken experimental design.</p><p><strong>Key results: </strong>The developed aptasensor demonstrated good performance with a limit of detection (LOD) and limit of quantification (LOQ) of 16 cells/mL and 3,882 cells/mL, respectively, in the K562 cell concentration range of 10<sup>2</sup> to 10<sup>6</sup> cells/mL. The optimum experimental conditions were an aptamer concentration of 0.8 ppm, an aptamer incubation time of 36 minutes, and a K562 aptamer-cell incubation time of 13 minutes. The aptasensor also exhibits selectivity for K562 cells compared to Vero cells, THP1 cells, and Raji cells.</p><p><strong>Conclusion: </strong>The aptasensor in this study demonstrated the potential to detect K562 cells. These results could contribute to the advancement of point-of-care (POC) devices for the detection of CML.</p>","PeriodicalId":7259,"journal":{"name":"ADMET and DMPK","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11517519/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ADMET and DMPK","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5599/admet.2404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background and purpose: Chronic myeloid leukaemia (CML) is one of the most lethal types of leukaemia and can rapidly progress if not treated properly. Therefore, having an effective diagnostic strategy is crucial. Various methods are available for diagnosis, including electrochemical biosensors with aptamer bioreceptors.
Experimental approach: In this study, we immobilized the KK1D04 aptamer on a screen-printed carbon electrode (SPCE) supported by CeO2 nanoparticles (CeO2NPs) to detect K562 cells, a type of CML cell line. Several parameters were optimized to enhance the aptasensor response using the Box-Behnken experimental design.
Key results: The developed aptasensor demonstrated good performance with a limit of detection (LOD) and limit of quantification (LOQ) of 16 cells/mL and 3,882 cells/mL, respectively, in the K562 cell concentration range of 102 to 106 cells/mL. The optimum experimental conditions were an aptamer concentration of 0.8 ppm, an aptamer incubation time of 36 minutes, and a K562 aptamer-cell incubation time of 13 minutes. The aptasensor also exhibits selectivity for K562 cells compared to Vero cells, THP1 cells, and Raji cells.
Conclusion: The aptasensor in this study demonstrated the potential to detect K562 cells. These results could contribute to the advancement of point-of-care (POC) devices for the detection of CML.
期刊介绍:
ADMET and DMPK is an open access journal devoted to the rapid dissemination of new and original scientific results in all areas of absorption, distribution, metabolism, excretion, toxicology and pharmacokinetics of drugs. ADMET and DMPK publishes the following types of contributions: - Original research papers - Feature articles - Review articles - Short communications and Notes - Letters to Editors - Book reviews The scope of the Journal involves, but is not limited to, the following areas: - physico-chemical properties of drugs and methods of their determination - drug permeabilities - drug absorption - drug-drug, drug-protein, drug-membrane and drug-DNA interactions - chemical stability and degradations of drugs - instrumental methods in ADMET - drug metablic processes - routes of administration and excretion of drug - pharmacokinetic/pharmacodynamic study - quantitative structure activity/property relationship - ADME/PK modelling - Toxicology screening - Transporter identification and study